141 related articles for article (PubMed ID: 35972341)
21. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
22. Negative remnant
Lan W; Gege Z; Ningning L; Qiang W; Lin B; Qingjie M; Bin J
Ann Nucl Med; 2019 Feb; 33(2):112-118. PubMed ID: 30374858
[TBL] [Abstract][Full Text] [Related]
23. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
25. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
26. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
[TBL] [Abstract][Full Text] [Related]
27. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
Wang C; Zhang X; Li H; Li X; Lin Y
PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
[TBL] [Abstract][Full Text] [Related]
28. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.
Bernier MO; Morel O; Rodien P; Muratet JP; Giraud P; Rohmer V; Jeanguillaume C; Bigorgne JC; Jallet P
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1418-21. PubMed ID: 16133388
[TBL] [Abstract][Full Text] [Related]
30. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
31. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer.
Albano D; Bonacina M; Durmo R; Bertagna F; Giubbini R
Endocrine; 2020 Apr; 68(1):124-131. PubMed ID: 31784881
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
34. Whole-remnant and maximum-voxel SPECT/CT dosimetry in
Mínguez P; Flux G; Genollá J; Delgado A; Rodeño E; Sjögreen Gleisner K
Med Phys; 2016 Oct; 43(10):5279-5287. PubMed ID: 28105713
[TBL] [Abstract][Full Text] [Related]
35. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
[TBL] [Abstract][Full Text] [Related]
36. Role of [
Xu Q; Liu R; Wang J; Huang Y; Li S; Zhang L; Wang F
Nucl Med Biol; 2020; 88-89():34-43. PubMed ID: 32688289
[TBL] [Abstract][Full Text] [Related]
37. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
38.
Giovanella L; Paone G; Ruberto T; Ceriani L; Trimboli P
Endocrinol Metab (Seoul); 2019 Mar; 34(1):63-69. PubMed ID: 30784242
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
[TBL] [Abstract][Full Text] [Related]
40. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
